- Home
- BMEA vs IMPP Comparison
BMEA vs IMPP Comparison
Compare BMEA & IMPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- IMPP
- Stock Information
- Founded
- BMEA 2017
- IMPP 1981
- Country
- BMEA United States
- IMPP Greece
- Employees
- BMEA N/A
- IMPP N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- IMPP Marine Transportation
- Sector
- BMEA Health Care
- IMPP Consumer Discretionary
- Exchange
- BMEA Nasdaq
- IMPP Nasdaq
- Market Cap
- BMEA 123.8M
- IMPP 171.4M
- IPO Year
- BMEA 2021
- IMPP N/A
- Fundamental
- Price
- BMEA $2.10
- IMPP $5.00
- Analyst Decision
- BMEA Strong Buy
- IMPP Strong Buy
- Analyst Count
- BMEA 9
- IMPP 1
- Target Price
- BMEA $15.44
- IMPP $5.50
- AVG Volume (30 Days)
- BMEA 698.1K
- IMPP 546.2K
- Earning Date
- BMEA 10-28-2025
- IMPP 09-05-2025
- Dividend Yield
- BMEA N/A
- IMPP N/A
- EPS Growth
- BMEA N/A
- IMPP N/A
- EPS
- BMEA N/A
- IMPP 1.02
- Revenue
- BMEA N/A
- IMPP $127,675,263.00
- Revenue This Year
- BMEA N/A
- IMPP $9.69
- Revenue Next Year
- BMEA N/A
- IMPP $51.33
- P/E Ratio
- BMEA N/A
- IMPP $4.90
- Revenue Growth
- BMEA N/A
- IMPP N/A
- 52 Week Low
- BMEA $1.29
- IMPP $2.12
- 52 Week High
- BMEA $13.07
- IMPP $5.25
- Technical
- Relative Strength Index (RSI)
- BMEA 59.89
- IMPP 77.88
- Support Level
- BMEA $1.97
- IMPP $4.28
- Resistance Level
- BMEA $2.10
- IMPP $5.25
- Average True Range (ATR)
- BMEA 0.11
- IMPP 0.30
- MACD
- BMEA 0.01
- IMPP 0.06
- Stochastic Oscillator
- BMEA 94.29
- IMPP 83.66
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.